Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
29.26 USD | -2.03% | +8.20% | -12.74% |
02:55pm | Pacira BioSciences Prices $250 Million Convertible Senior Notes Offering | MT |
May. 08 | Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.74% | 1.39B | |
+31.12% | 695B | |
+26.51% | 568B | |
-4.63% | 361B | |
+19.68% | 330B | |
+3.76% | 283B | |
+16.70% | 239B | |
+8.78% | 204B | |
-7.93% | 198B | |
+8.80% | 168B |
- Stock Market
- Equities
- PCRX Stock
- News Pacira BioSciences, Inc.
- RBC Cuts Price Target on Pacira BioSciences to $53 From $58, Keeps Outperform Rating